JP2021515015A5 - - Google Patents
Info
- Publication number
- JP2021515015A5 JP2021515015A5 JP2020546378A JP2020546378A JP2021515015A5 JP 2021515015 A5 JP2021515015 A5 JP 2021515015A5 JP 2020546378 A JP2020546378 A JP 2020546378A JP 2020546378 A JP2020546378 A JP 2020546378A JP 2021515015 A5 JP2021515015 A5 JP 2021515015A5
- Authority
- JP
- Japan
- Prior art keywords
- ray powder
- powder diffraction
- diffraction peaks
- angles
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639846P | 2018-03-07 | 2018-03-07 | |
| US62/639,846 | 2018-03-07 | ||
| PCT/US2019/021080 WO2019173551A1 (en) | 2018-03-07 | 2019-03-07 | Crystalline forms of an sgc stimulator |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515015A JP2021515015A (ja) | 2021-06-17 |
| JP2021515015A5 true JP2021515015A5 (enExample) | 2022-03-14 |
| JP7423539B2 JP7423539B2 (ja) | 2024-01-29 |
Family
ID=65818696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546378A Active JP7423539B2 (ja) | 2018-03-07 | 2019-03-07 | Ｓｇｃ刺激因子の結晶形態 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11466015B2 (enExample) |
| EP (1) | EP3762389B1 (enExample) |
| JP (1) | JP7423539B2 (enExample) |
| KR (1) | KR102782810B1 (enExample) |
| CN (1) | CN111836812A (enExample) |
| AU (1) | AU2019231724B2 (enExample) |
| BR (1) | BR112020018212A2 (enExample) |
| CA (1) | CA3092683A1 (enExample) |
| CL (5) | CL2020002284A1 (enExample) |
| CO (1) | CO2020012493A2 (enExample) |
| CR (1) | CR20200458A (enExample) |
| EA (1) | EA202092109A1 (enExample) |
| ES (1) | ES2980256T3 (enExample) |
| IL (1) | IL276853B2 (enExample) |
| MA (1) | MA54638A (enExample) |
| MX (5) | MX2020009183A (enExample) |
| PE (1) | PE20210124A1 (enExample) |
| PH (1) | PH12020551394A1 (enExample) |
| SG (1) | SG11202008641WA (enExample) |
| TW (1) | TWI823903B (enExample) |
| WO (1) | WO2019173551A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111836812A (zh) | 2018-03-07 | 2020-10-27 | 塞科里昂医疗股份有限公司 | sGC刺激剂的晶型 |
| US12220414B2 (en) * | 2018-07-11 | 2025-02-11 | Tisento Therapeutics Inc. | Use of sGC stimulators for the treatment of mitochondrial disorders |
| US20230130739A1 (en) * | 2020-03-26 | 2023-04-27 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
| CN118221651A (zh) * | 2022-12-21 | 2024-06-21 | 广东东阳光药业股份有限公司 | 氟取代的吲唑化合物的晶型及其用途 |
| AU2023412228A1 (en) * | 2022-12-21 | 2025-07-03 | Sunshine Lake Pharma Co., Ltd. | Crystal form of fluorine-substituted indazole compound and use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| CZ302691B6 (cs) | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| CN101939053A (zh) | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| CA2711134A1 (en) | 2008-01-24 | 2009-07-30 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| CA2743864A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2753434C (en) | 2009-02-26 | 2014-07-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| UA107112C2 (uk) | 2010-05-27 | 2014-11-25 | Мерк Шарп Енд Доме Корп. | Активатори розчинної гуанілатциклази |
| TWI532737B (zh) | 2010-06-30 | 2016-05-11 | 艾諾屋製藥公司 | 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物 |
| WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| JP5878546B2 (ja) | 2010-11-09 | 2016-03-08 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | ｓＧＣ刺激剤 |
| EP2927231B1 (en) | 2012-11-30 | 2017-09-20 | Astellas Pharma Inc. | Imidazopyridine compounds |
| US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
| CN104327107A (zh) * | 2013-10-17 | 2015-02-04 | 广东东阳光药业有限公司 | 一种氟喹诺酮类抗菌药物的制备方法 |
| US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| US10844064B2 (en) | 2014-09-17 | 2020-11-24 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| EP3227286B1 (de) * | 2014-12-02 | 2018-12-26 | Bayer Pharma Aktiengesellschaft | Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung |
| IL264955B (en) | 2016-09-02 | 2022-06-01 | Ironwood Pharmaceuticals Inc | Fused bicyclic sgc stimulators |
| CN111836812A (zh) | 2018-03-07 | 2020-10-27 | 塞科里昂医疗股份有限公司 | sGC刺激剂的晶型 |
-
2019
- 2019-03-07 CN CN201980017657.XA patent/CN111836812A/zh active Pending
- 2019-03-07 MX MX2020009183A patent/MX2020009183A/es unknown
- 2019-03-07 US US16/976,430 patent/US11466015B2/en active Active
- 2019-03-07 MX MX2023004856A patent/MX2023004856A/es unknown
- 2019-03-07 IL IL276853A patent/IL276853B2/en unknown
- 2019-03-07 EA EA202092109A patent/EA202092109A1/ru unknown
- 2019-03-07 AU AU2019231724A patent/AU2019231724B2/en active Active
- 2019-03-07 JP JP2020546378A patent/JP7423539B2/ja active Active
- 2019-03-07 MX MX2023004857A patent/MX2023004857A/es unknown
- 2019-03-07 MX MX2023004855A patent/MX2023004855A/es unknown
- 2019-03-07 BR BR112020018212-5A patent/BR112020018212A2/pt unknown
- 2019-03-07 MA MA054638A patent/MA54638A/fr unknown
- 2019-03-07 EP EP19712427.4A patent/EP3762389B1/en active Active
- 2019-03-07 CR CR20200458A patent/CR20200458A/es unknown
- 2019-03-07 KR KR1020207028170A patent/KR102782810B1/ko active Active
- 2019-03-07 TW TW108107664A patent/TWI823903B/zh active
- 2019-03-07 SG SG11202008641WA patent/SG11202008641WA/en unknown
- 2019-03-07 ES ES19712427T patent/ES2980256T3/es active Active
- 2019-03-07 MX MX2023004858A patent/MX2023004858A/es unknown
- 2019-03-07 WO PCT/US2019/021080 patent/WO2019173551A1/en not_active Ceased
- 2019-03-07 PE PE2020001347A patent/PE20210124A1/es unknown
- 2019-03-07 CA CA3092683A patent/CA3092683A1/en active Pending
-
2020
- 2020-09-03 CL CL2020002284A patent/CL2020002284A1/es unknown
- 2020-09-05 PH PH12020551394A patent/PH12020551394A1/en unknown
- 2020-10-06 CO CONC2020/0012493A patent/CO2020012493A2/es unknown
-
2021
- 2021-02-04 CL CL2021000301A patent/CL2021000301A1/es unknown
- 2021-12-28 CL CL2021003530A patent/CL2021003530A1/es unknown
- 2021-12-28 CL CL2021003531A patent/CL2021003531A1/es unknown
- 2021-12-28 CL CL2021003536A patent/CL2021003536A1/es unknown
-
2022
- 2022-09-28 US US17/954,713 patent/US12122782B2/en active Active
-
2024
- 2024-10-21 US US18/921,161 patent/US20250115611A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013237682A5 (enExample) | ||
| JP2022520382A5 (enExample) | ||
| JP2022525759A5 (enExample) | ||
| WO2018081417A3 (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| JP2006316058A5 (enExample) | ||
| JP2016504392A (ja) | 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体 | |
| CA2608018A1 (en) | Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | |
| JP2018516883A5 (enExample) | ||
| JP2018168191A5 (enExample) | ||
| JP2015010091A5 (enExample) | ||
| JP2015193630A5 (enExample) | ||
| JP2015522037A5 (enExample) | ||
| EA025863B1 (ru) | Карбазолкарбоксамидные соединения | |
| JP2017531680A (ja) | 三環式アトロプ異性体の化合物 | |
| JP2022507533A5 (enExample) | ||
| CA2647346A1 (en) | Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | |
| PH12020551394A1 (en) | CRYSTALLINE FORMS OF AN sGC STIMULATOR | |
| JP2011527687A5 (enExample) | ||
| RU2004133811A (ru) | Новые соединения | |
| JP2018516946A5 (enExample) | ||
| IL266097B (en) | Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine | |
| JP2023524518A5 (enExample) | ||
| JP2016510767A5 (enExample) | ||
| JP2022525102A5 (enExample) | ||
| JP2004530660A5 (enExample) |